These are the stocks posting the largest moves before the bell.Market Insiderread more
But the bank's net interest margin, a key metric of bank profitability, falls short of expectations.Financeread more
Citi Research has an 18-item checklist to identify whether global markets are entering into a "bear period."Investingread more
The CEO of railroad operator CSX is sounding alarm on the U.S. economy, calling it "unusual" and "puzzling" as it weighs on the company's shipping volumes.Marketsread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
"Here's what I think is true: Google refused to work for the Pentagon on artificial intelligence" and it works on AI in China, says Richard Clarke.Technologyread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
Here are the biggest calls on Wall Street on WednesdayInvestingread more
The EU opened a formal antitrust investigation into Amazon on Wednesday centered on how the e-commerce giant uses merchants' data.Technologyread more
Turo is a peer-to-peer car-sharing firm that is often referred to as the Airbnb for cars.Technologyread more
Mortgage interest rates surged last week to their highest level in a month, and consequently homebuyers turned on their heels.Real Estateread more
WASHINGTON, Feb 5 (Reuters) - A bipartisan group of U.S. senators re-introduced a bill on Tuesday aimed at helping generic drug companies bring out a cheaper version of pharmaceuticals.
Makers of branded drugs have long been accused of refusing to provide samples of drugs on a government list of restricted medicines. Without the samples, generic competitors cannot prove their medicines are as safe and effective as the more expensive versions.
To combat this, Republican Senators Chuck Grassley and Mike Lee and Democrat Amy Klobuchar and some two dozen other senators from both sides of the aisle introduced a bill that spells out a legal pathway for generic companies to press for the samples.
In the U.S. House of Representatives, Rep. David Cicilline, a Democrat, and Jim Sensenbrenner, a Republican, and others introduced an identical measure.
The bill is one of several aimed at bringing down, or at least containing, the high and rising price of many medicines. It was considered in the previous Congress but failed to become law. (Reporting by Diane Bartz in Washington Editing by James Dalgleish)